Response to: monoclonal antibodies targeting CD20

Affiliations

¹ Discovery Oncology; Pharma Research and Early Development (pRED); Roche Glycart AG; Schlieren, Switzerland.
² Department of Chemistry and Biochemistry; Gene Center; Ludwig-Maximilians University Munich; Munich, Germany.
³ Large Molecule Research; Pharma Research and Early Development (pRED); Roche Diagnostics GmbH; Penzberg, Germany.
⁴ Discovery Oncology; Pharma Research and Early Development (pRED); Roche Diagnostics GmbH; Penzberg, Germany.

Comment

Christian Klein et al. MAbs. 2013 May-Jun.

. 2013 May-Jun;5(3):337-8.

doi: 10.4161/mabs.24108. Epub 2013 Mar 14.

¹ Discovery Oncology; Pharma Research and Early Development (pRED); Roche Glycart AG; Schlieren, Switzerland.
² Department of Chemistry and Biochemistry; Gene Center; Ludwig-Maximilians University Munich; Munich, Germany.
³ Large Molecule Research; Pharma Research and Early Development (pRED); Roche Diagnostics GmbH; Penzberg, Germany.
⁴ Discovery Oncology; Pharma Research and Early Development (pRED); Roche Diagnostics GmbH; Penzberg, Germany.

No abstract available

Comment on

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.
Klein C, Lammens A, Schäfer W, Georges G, Schwaiger M, Mössner E, Hopfner KP, Umaña P, Niederfellner G. Klein C, et al. MAbs. 2013 Jan-Feb;5(1):22-33. doi: 10.4161/mabs.22771. Epub 2012 Dec 4. MAbs. 2013. PMID: 23211638 Free PMC article.
Monoclonal antibodies targeting CD20.
Chang CH, Rossi EA, Goldenberg DM. Chang CH, et al. MAbs. 2013 May-Jun;5(3):335-6. doi: 10.4161/mabs.24106. Epub 2013 Mar 14. MAbs. 2013. PMID: 23493149 Free PMC article. No abstract available.

1. Mayes S, Brown N, Illidge TM. New antibody drug treatments for lymphoma. Expert Opin Biol Ther. 2011;11:623–40. doi: 10.1517/14712598.2011.560569. - DOI - PubMed
1. Jain P, O'Brien S. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. Expert Opin Biol Ther. 2013;13:169–1822. doi: 10.1517/14712598.2012.735655. - DOI - PubMed
1. van Meerten T, Hagenbeek A. CD20-targeted therapy: the next generation of antibodies. Semin Hematol. 2010;47:199–210. doi: 10.1053/j.seminhematol.2010.01.007. - DOI - PubMed
1. Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood. 2009;113:1062–70. doi: 10.1182/blood-2008-07-168146. - DOI - PMC - PubMed
1. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin’s lymphoma: phase I/II results. J Clin Oncol. 2009;27:3346–53. doi: 10.1200/JCO.2008.19.9117. - DOI - PubMed